{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:12:47Z","timestamp":1761520367333,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clcc.2023.12.001","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T22:02:37Z","timestamp":1702159357000},"page":"73-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Impact of Primary Tumor Sidedness in Stage III Colorectal Cancer: Real-World Evidence from a Brazilian Cohort"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-0234","authenticated-orcid":false,"given":"Bruno Medon\u00e7a","family":"Prot\u00e1sio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago Biachi","family":"de Castria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Natalino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1via R.","family":"Mangone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Fernandes","family":"Saragiotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Sabbaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo M.","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Chammas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.clcc.2023.12.001_bib0001","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"Engl J Med"},{"issue":"19","key":"10.1016\/j.clcc.2023.12.001_bib0002","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clcc.2023.12.001_bib0003","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","article-title":"Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07","volume":"25","author":"Kuebler","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clcc.2023.12.001_bib0004","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer","volume":"29","author":"Haller","year":"2011","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.clcc.2023.12.001_bib0005","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2015.60.9107","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid as adjuvant therapy for stage iii colon cancer: final results of the NO16968 randomized controlled phase iii trial","volume":"33","author":"Schmoll","year":"2015","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clcc.2023.12.001_bib0006","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2023.12.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3504","article-title":"Impact of primary (1\u00b0) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (PTS) with metastatic colorectal cancer (mCRC): analysis of CALGB\/SWOG 80405 (Alliance)","volume":"34","author":"Venook","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2023.12.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3505","article-title":"The relationship between primary tumor sidedness and prognosis in colorectal cancer","volume":"34","author":"Schrag","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clcc.2023.12.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3695","article-title":"Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status","volume":"4","author":"Taieb","year":"2018","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.clcc.2023.12.001_bib0010","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1158\/1078-0432.CCR-15-0527","article-title":"Analysis of molecular markers by anatomic tumor site in stage III colon carcinomas from adjuvant chemotherapy trial NCCTG N0147 (Alliance)","volume":"21","author":"Sinicrope","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.001_bib0011","first-page":"65","article-title":"Safety and efficacy of a modified FLOX adjuvant regimen for patients with stage iii colorectal cancer treated in the community","volume":"16","author":"Prot\u00e1sio","year":"2017","journal-title":"Clin Colorectal Cancer"},{"first-page":"73","year":"2017","series-title":"TNM Classification of Malignant Tumours","key":"10.1016\/j.clcc.2023.12.001_bib0012"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.001_bib0013","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/jclinpath-2014-202691","article-title":"Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients","volume":"68","author":"Malapelle","year":"2015","journal-title":"J Clin Pathol"},{"issue":"41","key":"10.1016\/j.clcc.2023.12.001_bib0014","doi-asserted-by":"crossref","first-page":"26279","DOI":"10.18632\/oncotarget.25180","article-title":"KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B\/FOx adding bevacizumab (BEV) to triplet chemotherapy","volume":"9","author":"Bruera","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.clcc.2023.12.001_bib0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0002-9440(10)63841-2","article-title":"Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors","volume":"162","author":"Hendriks","year":"2003","journal-title":"Am J Pathol"},{"issue":"20","key":"10.1016\/j.clcc.2023.12.001_bib0016","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1200\/JCO.2009.27.0652","article-title":"Clinical relevance of microsatellite instability in colorectal cancer","volume":"28","author":"de la Chapelle","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clcc.2023.12.001_bib0017","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clcc.2023.12.001_bib0018","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","article-title":"Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials","volume":"21","author":"Andr\u00e9","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clcc.2023.12.001_bib0019","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(14)70227-X","article-title":"Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial","volume":"15","author":"Taieb","year":"2014","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.clcc.2023.12.001_bib0020","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2012.385","article-title":"Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial","volume":"307","author":"Alberts","year":"2012","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.clcc.2023.12.001_bib0021","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1200\/JCO.18.01798","article-title":"Mutational analysis of patients with colorectal cancer in CALGB\/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome","volume":"37","author":"Innocenti","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clcc.2023.12.001_bib0022","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/annonc\/mdx052","article-title":"Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study","volume":"28","author":"Dienstmann","year":"2017","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.clcc.2023.12.001_bib0023","article-title":"Primary tumor location as an independent prognostic marker from molecular features for overall survival in patients with metastatic colorectal cancer: analysis of CALGB\/SWOG 80405 (Alliance)","volume":"35","author":"Venook","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002823001238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002823001238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:08:38Z","timestamp":1761520118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002823001238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1533002823001238"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2023.12.001","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Impact of Primary Tumor Sidedness in Stage III Colorectal Cancer: Real-World Evidence from a Brazilian Cohort","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}